COVID-19
Sections
-
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) C...
-
ResApp announces positive results for a new novel smartphone-based COVID-19 screening test
23/03/2022
ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone. -
Thousands of Australians at risk of progressing to severe COVID-19 disease1 will now be eligible to access an oral antiviral treatment taken over five days through the Pharmaceutical Benefits Scheme (PBS).2
-
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted provisional approval of NVX-CoV2373, Novavax' COVID-19 vaccine (adjuvanted), for activ...
-
Unemployment rates across the globe have dramatically risen, yet despite that, so many countries have chosen to ignore COVID and do their best to recover economically.
-
NovaBiotics announces fast-track repurposing of its experimental drug Nylexa for COVID-19 trials ...
14/04/2020
NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections. -
Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
-
FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WI...
9/04/2020
Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it has received clearance from the United States Food and Drug Administration (FDA) -
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose...
8/04/2020
Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 -
Celltrion Healthcare secure 300 COVID-19 antibody candidates in efforts to develop antiviral
8/04/2020
Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month... -
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to el...
-
Researchers at the University of East Anglia are launching a new project to track the health of the nation during lockdown, and they are looking for volunteers to take part.
-
CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.
-
At this challenging time, we at PharmiWeb are pleased to step forward and do our small part by helping the NHS recruit urgently needed staff for the battle against COVID-19.
-
ZEGAMI BUILDS NEW TECH PLATFORM TO ANALYSE COVID-19 X-RAYS TO HELP SPEED UP DIAGNOSIS AND POTENTI...
7/04/2020
Zegami, the Oxford University data visualisation spin-out, has developed a new machine learning model using x-rays of Covid-19 infected lungs, artificial intelligence techniques and data visualisation tools that could help medical professionals identify Coronavirus cases more effectively, but als... -
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.
-
The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants
-
APEIRON Biologics AG today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19
-
EUSA PHARMA AND PAPA GIOVANNI XXIII HOSPITAL, ITALY, PROVIDE INTERIM ANALYSIS DATA FOR SILTUXIMAB...
1/04/2020
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO (Siltuximab In Serious COVID-19) Study,1 based on a pre-planned data analysis on 24 March 2020.